Johnson & Johnson (JNJ) Return on Capital Employed (2009 - 2026)
Johnson & Johnson (JNJ) posted Return on Capital Employed of 28.18% for Q1 2026, little changed sequentially from 28.14% in Q4 2025, and up 1180.0% YoY from 2.2% in Q1 2025.
Johnson & Johnson (JNJ) Return on Capital Employed (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Return on Capital Employed data on file, last reported at 28.18% in Q1 2026.
- Quarterly Return on Capital Employed rose 1180.0% year-over-year to 28.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28.18% (up 1180.0% YoY) and the FY2025 annual result came in at 29.46%, up 1244.0% from the prior year.
- Return on Capital Employed was little changed at 28.18% in Q1 2026 per JNJ's latest filing, from 28.14% in the prior quarter.
- The five-year high for Return on Capital Employed was 30.16% in Q2 2024, with the low at 15.38% in Q4 2022.
- Average Return on Capital Employed over 5 years is 21.41%, with a median of 18.66% recorded in 2023.
- The widest YoY moves for Return on Capital Employed: up 1183 bps in 2025, down 1476 bps in 2025.
- Johnson & Johnson's Return on Capital Employed stood at 15.38% in 2022, then surged by 95 bps to 29.97% in 2023, then plunged by 46 bps to 16.31% in 2024, then surged by 73 bps to 28.14% in 2025, then advanced by 0 bps to 28.18% in 2026.
- Business Quant data shows JNJ's Return on Capital Employed at 28.18% in Q1 2026, 28.14% in Q4 2025, and 16.49% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 42.94% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 28.18% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 16.47% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.76% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -10.20% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -3.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 28.18% |
| Dec 28, 2025 | 28.14% |
| Sep 28, 2025 | 16.49% |
| Jun 29, 2025 | 15.40% |
| Mar 30, 2025 | 16.38% |
| Dec 29, 2024 | 16.31% |
| Sep 29, 2024 | 28.35% |
| Jun 30, 2024 | 30.16% |
| Mar 31, 2024 | 30.00% |
| Dec 31, 2023 | 29.97% |
| Oct 1, 2023 | 19.98% |
| Jul 2, 2023 | 18.93% |
| Apr 2, 2023 | 18.66% |
| Jan 1, 2023 | 18.44% |
| Oct 2, 2022 | 15.38% |
| Jul 3, 2022 | 15.79% |
| Apr 3, 2022 | 17.37% |
| Oct 3, 2021 | 20.67% |
| Jul 4, 2021 | 19.67% |
| Apr 4, 2021 | 18.45% |